from

Candi Solar Secures USD 58.5 Million from International Finance Corporation (IFC) to Power Next Growth Phase

Candi Solar, a leading clean energy company specialising in distributed solar solutions for commercial and industrial (C&I) businesses, has secured…

18 hours ago

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

– Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET – December 14,…

2 days ago

12,000 Students from 15 Nations Celebrate Ryan Group’s Golden Jubilee in Mumbai

MUMBAI, India, Dec. 13, 2025 /PRNewswire/ -- Mumbai's Fine Arts Centre, came alive as the 21st Ryan International Children's Festival…

3 days ago

IOC receives Low Carbon Award from Geneva climate network 2050Today

11 december 2025 - In recognition of its progress in reducing its corporate carbon footprint by 30%, the International Olympic…

3 days ago

From ‘Make in India’ to ‘Design for India’: Ajay Piramal Charts a Vision for Nation-Building at Anant National University

AHMEDABAD, India, Dec. 12, 2025 /PRNewswire/ -- Anant National University celebrated its 7th Convocation, awarding degrees to 299 students across…

4 days ago

From the Capital of Capital, ADFW Charts the Next Frontier in Asset Management

ABU DHABI, UAE, Dec. 9, 2025 /PRNewswire/ -- Abu Dhabi Finance Week (ADFW), the flagship event hosted by ADGM, continued…

7 days ago

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF)…

1 week ago

TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

December 06, 2025 17:30 ET  | Source: TScan Therapeutics, Inc. Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23)…

1 week ago

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

December 06, 2025 17:30 ET  | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…

1 week ago

Inside GAC: African Media Witness Intelligence, Precision, and Quality

GUANGZHOU, China, Dec. 1, 2025 /PRNewswire/ -- From November 19 to 21, a delegation of leading African automotive media representatives from…

2 weeks ago